185 related articles for article (PubMed ID: 19509354)
1. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
2. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis as a therapeutic target in urothelial carcinoma.
Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis regulated by VEGF and its receptors and its clinical application.
Shibuya M
Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
[No Abstract] [Full Text] [Related]
5. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
6. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
7. [Anti-angiogenic drugs].
Sato Y
Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Sessa C; Guibal A; Del Conte G; Rüegg C
Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
10. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
11. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
12. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
13. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
14. Therapeutic advances in women's cancers.
Carroll AR; Coleman RL; Sood AK
Front Biosci (Schol Ed); 2011 Jan; 3(1):82-97. PubMed ID: 21196359
[TBL] [Abstract][Full Text] [Related]
15. Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Marx J
Science; 2005 May; 308(5726):1248-9. PubMed ID: 15919970
[No Abstract] [Full Text] [Related]
16. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
Bennis Y; Guillet B; Curti C; Pisano P
Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
20. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Döme B; Magyar M
Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]